Loading…
← CockpitCompetitor Analysis › 002793.SZ Luoxin Pharmaceuticals Group Stock Co., Ltd. Class AOpen in the cockpit ↗

Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A002793.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 28
Mkt cap
$609M
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$9.83M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-8.6 pp
WACC 6.2%
Hurdle
+17 pp
Req g minus delivered
Close · CNYCN¥3.80
1D-0.5%
1W-5.5%
1M-13.2%
3M-28.0%
6M-25.9%
YTD-20.8%
1Y-29.8%
ATR %3.8%
52w lowhigh34.7% off high

What Luoxin Pharmaceuticals Group Stock does

Employees: 2,962

Luoxin Pharmaceuticals Group Stock at a glance

Size Luoxin Pharmaceuticals Group Stock (002793.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $609M, the 3207th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.80 on 18 Nov 2026.

Performance Over six months the shares fell 25.9%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue fell 10.3% over the last twelve months (peer median +3.7%); the operating margin is -8.9% (peer median 4.4%).

Valuation It trades at 2.0× enterprise value to sales against a peer median of 3.1× (5th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -18%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.6 points below its cost of capital (6.2% WACC).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026002793.SZ 76Peer median 75
Six months, rebased to 100: Luoxin Pharmaceuticals Group Stock against the median of its 20 peers (local-currency closes).

Luoxin Pharmaceuticals Group Stock financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.23BCN¥2.26BCN¥2.64BCN¥2.36BCN¥3.57B
Revenue growth—-15%+12%-34%—
Gross profitCN¥1.31BCN¥1.04BCN¥1.05BCN¥981MCN¥792M
EBITDAn/aCN¥48.1M-CN¥577M-CN¥268M-CN¥1.33B
Net income-CN¥250M-CN¥289M-CN¥965M-CN¥661M-CN¥1.22B
Free cash flowCN¥287MCN¥221M-CN¥273MCN¥310M-CN¥1.13B
Capital expenditureCN¥34.5MCN¥32.2MCN¥115MCN¥242MCN¥195M
Total debtCN¥1.53BCN¥1.27BCN¥1.72BCN¥1.52BCN¥3.70B

Quarterly statements and history in the cockpit →

Luoxin Pharmaceuticals Group Stock competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%185750603567002940300194ORCHPHARMADBV3002334105OLMA301211600976IMMXBCAX300147300878CGEM603439002793.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Luoxin Pharmaceuticals Group Stock is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×10×20×185750603567002940ORCHPHARMA300233301096300147ABUS300878002793.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Luoxin Pharmaceuticals Group Stock is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%1857506035670029403001943002334105300147603439002793.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Luoxin Pharmaceuticals Group Stock is the large dot.

Luoxin Pharmaceuticals Group Stock competitors and peer comparison

How Luoxin Pharmaceuticals Group Stock compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Luoxin Pharmaceuticals Group Stock against its 20 peers (data as of 18 Nov 2026)
Measure002793.SZPeer medianRank in peer set
1-month return-13.2%-10.2%5th lowest of 20
6-month return-25.9%-26.6%10th highest of 20
Distance from 52-week high-34.7%-43.9%7th highest of 20
Revenue growth (TTM)-10.3%+3.7%3rd lowest of 15
Operating margin-8.9%4.4%4th lowest of 14
EV / Sales2.0×3.1×5th cheapest of 15
Growth the price implies (Req g, 7 yrs)-1.0%9.1%4th least demanding of 10
Growth delivered (Del g)-17.9%+2.1%2nd lowest of 10
Hurdle (Req g minus delivered)+16.9 pp+1.0 pp4th most demanding of 10
ROIC minus cost of capital-8.6 pp-3.9 pp5th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%

Questions

Which companies are Luoxin Pharmaceuticals Group Stock's closest peers?
The cockpit's peer set: Chongkundang (185750.KS), Achieve Life Sciences (QUIT), HeiLongJiang ZBD Pharmaceutical (603567.SS), Zhejiang Anglikang Pharmaceutical (002940.SZ), Fuan Pharmaceutical (Group) (300194.SZ), Orchid Pharma (ORCHPHARMA.NS), DBV Technologies (DBV.PA), Shandong Jincheng Pharmaceutical (300233.SZ).
Is Luoxin Pharmaceuticals Group Stock expensive compared with its peers?
On ev / sales it trades at 2.0× against a peer median of 3.1×, 5th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -18%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Luoxin Pharmaceuticals Group Stock stock performed?
Over six months to 18 Nov 2026 the shares returned -25.9% against -26.6% for the median peer; over one year -29.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.